Sinopharm Tech Holdings Limited stock analysis
Want to see HK:8156 full AI Analyst Report?
Sinopharm Tech Holdings Limited (8156) Stock Price & Analysis
8156 Stock Chart & Stats
- Day’s Range
- HKD 0.11 - HKD 0.16
- 52-Week Range
- HKD 0.06 - HKD 0.36
- Previous Close
- HKD 0.14
- Volume
- N/A
- Average Volume (3M)
- 31.53K
- Market Cap
- HKD 96.96M
- Enterprise Value
- HKD 173.64M
- Total Cash (Recent Filing)
- HKD 5.62M
- Total Debt (Recent Filing)
- HKD 30.73M
- Price to Earnings (P/E)
- ―
- Beta
- 0.32
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt Reduction
Debt has declined from prior-year levels, which is a constructive balance-sheet development and could gradually reduce financing pressure if sustained. However, the improvement remains limited because debt is still meaningful relative to assets and the company continues to have negative equity.
Improving Free Cash Flow Trend
The year-over-year improvement in free cash flow indicates some progress in cash management compared with the preceding period. If maintained, this could support operations and eventual deleveraging, although current cash generation remains insufficient to provide dependable financial support.
Losses Less Severe Than Earlier Years
Although the company remains unprofitable, losses are less severe than the notably weaker results reported in 2021 and 2022. This suggests some historical recovery in earnings performance, but the latest revenue decline and negative margins show that the improvement is not yet durable.
Bears Say
Sharp Revenue Contraction
The steep 2026 revenue decline highlights significant instability in the company’s commercial performance and weakens earnings visibility. A contraction of this magnitude can reduce operating leverage, limit reinvestment capacity, and make a sustained recovery more difficult over the next several quarters.
Negative Equity And Balance-Sheet Stress
Persistently negative shareholders’ equity materially restricts financial flexibility and indicates that liabilities exceed the recorded asset base. Meaningful debt alongside this equity deficit increases balance-sheet vulnerability and may constrain the company’s ability to fund operations or pursue growth internally.
Unprofitable Operations
Low gross margins combined with negative operating and net margins show that the core business is not currently converting revenue into sustainable earnings. Continued operating losses weaken internal funding capacity and make financial improvement dependent on a meaningful recovery in revenue or margins.
8156 FAQ
What was Sinopharm Tech Holdings Limited’s price range in the past 12 months?
What is Sinopharm Tech Holdings Limited’s market cap?
When is Sinopharm Tech Holdings Limited’s upcoming earnings report date?
How were Sinopharm Tech Holdings Limited’s earnings last quarter?
Is Sinopharm Tech Holdings Limited overvalued?
Does Sinopharm Tech Holdings Limited pay dividends?
What is Sinopharm Tech Holdings Limited’s EPS estimate?
How many shares outstanding does Sinopharm Tech Holdings Limited have?
What happened to Sinopharm Tech Holdings Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sinopharm Tech Holdings Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Sinopharm Tech Holdings Limited
Sinopharm Tech Holdings Limited functions as an investment holding enterprise, with its primary focus on lottery operations across mainland China and Hong Kong. The company diversifies its activities into several key areas: it supplies both hardware and software systems for lottery services; develops and implements "Internet Plus" solutions for various industries including healthcare, government administration, property leasing, and public security; engages in the manufacturing and distribution of personal protective equipment; and offers additional services such as corporate management, supply chain optimization, data analytics, and online trading of goods. Founded in 1999 and headquartered in Sha Tin, Hong Kong, the company rebranded to Sinopharm Tech Holdings Limited in June 2019, having previously traded as China Vanguard You Champion Holdings Limited.
- Sector
- Technology
- Industry
- Software - Application
- CEO
- Shuk Yi Kwok
- Employees
- 31
- Website
- www.sinopharmtech.com.hk
- Address
- HK
Sinopharm Tech Holdings Limited (8156) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 3 | 12 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 2 | 0 | 10 |

